Celsion Corporation Stock News

R0 (Complete) Surgical Resection Rates for Patients Randomized to GEN-1 Treatment Arm Compare Favorably to Patients Receiving Neoadjuvant Chemotherapy Only Company to.

Celsion Corporation (CLSN), a leading oncology drug development company, announces that Michael H. Tardugno, the company’s chairman, president and chief executive officer, issued the following lette

Big Lots (NYSE:BIG) -35% on Q4 earnings.Tonix Pharmaceuticals (NASDAQ:TNXP) -23% after pricing stock offering.Celsion (NASDAQ:CLSN) -19% after pricing registered direct offering.Wayfair (NY

The Company has also agreed to issue to such investors, in a concurrent private placement, warrants to purchase 2,971,428 shares of the Company’s common stock. The gross proceeds of the offering wi

Celsion Corporation's (NASDAQ:CLSN): Celsion Corporation, a development stage oncology drug company, focuses on the...

Ziopharm announced a dilutive secondary share offering. Gilead's earnings call and new strategy. Celsion has new safety data.

Celsion Corporation (CLSN) today announced that the independent Data Safety Monitoring Board (DSMB) has completed its initial safety review of data from the first fifteen patients treated with the fi

Celsion Corporation (CLSN), an oncology drug-development company, announces that Prof. Riccardo Lencioni, M.D., FSIR, EBIR delivered a presentation titled “Thermally-Sensitive Ablation Enhancers: Wh

If you're interested in Celsion Corporation (NASDAQ:CLSN), then you might want to consider its beta (a measure of...

Alexion (ALXN) plans to initiate a phase III study on Ultomiris (ravulizumab) to treat amyotrophic lateral sclerosis.